Peak XV Partners and Portsmouth Technologies executed significant bulk deals on October 9, 2026, leading to a shift in institutional holdings for Awfis Space Solutions and Anthem Biosciences. While Awfis shares showed resilience despite the sale, Anthem Biosciences faced downward pressure. Investors should track these institutional moves as they may reflect shifting confidence or portfolio rebalancing strategies.
On October 9, 2026, the Indian stock market saw significant institutional activity as major investors reshuffled their portfolios through bulk deals. Peak XV Partners Investments V and Portsmouth Technologies LLC were among the key sellers, offloading shares in Awfis Space Solutions and Anthem Biosciences, respectively.
Peak XV Trims Awfis Position
Peak XV Partners Investments V sold 704,663 shares of the workspace provider Awfis Space Solutions. The transaction was executed at a price of ₹245.00 per share. Interestingly, the stock market responded with resilience to this news, as Awfis shares closed higher on the day. For investors, this suggests that the supply created by the institutional sale was absorbed by other market participants. However, it is important for shareholders to monitor the company’s business model carefully. The firm is currently in a phase of rapid center expansion, which often leads to higher debt levels, rising finance costs, and increased depreciation, all of which can impact long-term profit margins.
Portsmouth Tech Liquidates Anthem Biosciences Stake
Portsmouth Technologies LLC executed a much larger transaction, selling 3,000,000 shares of Anthem Biosciences. This deal, valued at approximately ₹249.9 crore, occurred at an average price of ₹833.00 per share. Unlike the movement seen in Awfis, this sell-off exerted downward pressure on Anthem Biosciences. Shares of the company fell by 1.17%, closing the session at ₹862.30.
Investor Risks and Market Context
Institutional selling of this magnitude often catches the attention of market participants, as it can sometimes signal a change in the long-term investment thesis. For Anthem Biosciences, a key point of discussion among analysts and investors has been its valuation. The company has historically traded at a high price-to-earnings (P/E) ratio, often exceeding 80. High-valuation stocks in the biotechnology sector can be more sensitive to negative news or large block sales, as even minor shifts in sentiment can trigger volatility.
For investors, the most useful approach is to look beyond the daily stock movement. Institutional investors frequently rebalance their portfolios for reasons unrelated to the specific company's performance, such as meeting redemption demands or shifting sector allocations. The next important step for shareholders is to watch for upcoming quarterly financial results and management commentary. These updates will provide clearer insights into whether the operational performance of these companies remains on track or if the institutional selling reflects concerns about future growth, debt management, or sustaining high profit margins.